Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/22q11.2 Deletion Syndrome

Other

22q11.2 Deletion Syndrome (VCFS) Clinical Trials

Also called DiGeorge syndrome, Velocardiofacial syndrome, VCFS

22q11.2 deletion syndrome (also called DiGeorge syndrome or velocardiofacial syndrome) results from a 1.

In plain words, 22q11.2 deletion syndrome happens when a small piece of chromosome 22 is missing. Signs vary but can include heart defects and an opening in the roof of the mouth, plus immune and learning problems.

Get an email when new 22q11.2 Deletion Syndrome trials open or the FDA decides. Get alerts

22q11.2 Deletion Syndrome

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 6 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names 22q11.2 Deletion Syndrome yet.

22q11.2 Deletion Syndrome has no FDA-approved medicines, 8 open or active clinical trials (8 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for 22q11.2 Deletion Syndrome

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about 22q11.2 Deletion Syndrome

5-3 Mb microdeletion on chromosome 22q11.2, affecting approximately 50 genes. This is the most common recurrent microdeletion in humans, occurring in approximately 1 in 2,000-4,500 people. The deletion results from non-allelic homologous recombination between low copy repeats (LCRs) flanking the 22q11.2 region.

Keep reading about 22q11.2 Deletion Syndrome

Clinical manifestations are highly variable due to variable breakpoints and gene dosage effects, even among family members.

The 'CATCH-22' mnemonic describes cardinal features: Cardiac defects (occurring in ~75-80%, especially conotruncal abnormalities including tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch), Abnormal facies (dysmorphic features), Cleft palate or velopharyngeal insufficiency (occurring in ~30-40%), Thymic hypoplasia (causing variable immunodeficiency in ~75%), Hypocalcemia (from parathyroid hypoplasia in ~50%), and 22q11 deletion.

Additional features include learning disability and developmental delay (occurring in ~70%), speech delays, hearing loss, renal anomalies, and increased psychiatric manifestations particularly schizophrenia.

What are the symptoms of 22q11.2 Deletion Syndrome?

These are common symptoms of 22q11.2 Deletion Syndrome, and how strong they are varies from person to person.

  • Cardiac defects (conotruncal abnormalities, especially Tetralogy of Fallot)
  • Cleft palate and velopharyngeal insufficiency
  • Immune deficiency from thymic hypoplasia
  • Hypocalcemia and hypoparathyroidism
  • Intellectual and developmental disability
  • Learning problems and speech delays

Who gets 22q11.2 Deletion Syndrome?

22q11.2 deletion syndrome shows autosomal dominant inheritance; approximately 90% of cases represent de novo (new) mutations, while approximately 10% are inherited from an affected parent with variable expressivity.

The condition affects males and females equally. The deletion occurs across all ethnic groups and geographic populations without significant population predisposition or founder effects. Prognosis varies significantly based on the specific genes involved and the presence or severity of cardiac abnormalities, immunodeficiency, and psychiatric manifestations.

Early diagnosis (through prenatal diagnosis, newborn screening, or clinical recognition in infancy) enables preventive measures and early intervention. Recurrence risk for unaffected parents is <1%; for an affected parent, the recurrence risk is 50% per pregnancy (though expressivity is variable). Germline mosaicism has been reported rarely in phenotypically normal parents.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for 22q11.2 Deletion Syndrome

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted 22q11.2 Deletion Syndrome resources

Reputable organizations and medical references for learning more about 22q11.2 Deletion Syndrome, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for 22q11.2 Deletion Syndrome

Use this 22q11.2 Deletion Syndrome clinical trial finder to see the 8 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 5 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

8 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT07643896

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

Sponsor: BillionToOne Inc.

The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic ...

Ages not specified
Started Jan 2026Updated 1 month agoEst. Dec 2027 (~1y 1m)
RecruitingObservational study, no treatment givenUpdated a few months agoNCT00556530

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

Sponsor: Albert Einstein College of Medicine

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to id...

Ages not specified1 location
Started Jul 2016Updated 3 months agoEst. Jun 2029 (~2y 7m)
RecruitingTreatment trialPhase 2No updates in a whileNCT07284641

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Intervention: Hematopoietic stem cell transplant (HSCT)

Sponsor: Paul Szabolcs

This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD).

Ages 5 Years to 40 Years1 location
Started May 2026Updated 6 months agoEst. May 2030 (~3y 5m)
RecruitingPatient registry covering many conditionsNo updates in a whileNCT07493096

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

Sponsor: Healing Hope International

This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral...

Ages 4 Years to 12 Years1 location
Started Mar 2026Updated 7 months agoEst. Jan 2028 (~1y 1m)
RecruitingTreatment trialPhase 4No updates in a whileNCT00768820

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

Intervention: methylphenidate, fluoxetin, risperidone

Sponsor: The Chaim Sheba Medical Center

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Ages not specified1 location
Started May 2001Updated 8 months agoEst. Aug 2027 (~9 months)
Find 22q11.2 Deletion Syndrome trials near you, ranked by distance →
Active trial locations11 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+3 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about 22q11.2 Deletion Syndrome trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a 22q11.2 Deletion Syndrome foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

22q11.2 Deletion Syndrome patient communities

Facebook groups, Reddit communities and YouTube channels where 22q11.2 Deletion Syndrome patients, caregivers and advocacy groups talk.

Questions people ask about 22q11.2 Deletion Syndrome